Mesoblast Limited (MEOBF)
USD 1.37
(-52.76%)
USD 1.37
(-52.76%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 5.9 Million USD | -92.31% |
| 2023 | 76.79 Million USD | -15.42% |
| 2022 | 90.78 Million USD | -21.1% |
| 2021 | 115.05 Million USD | 6.97% |
| 2020 | 107.56 Million USD | 9.89% |
| 2019 | 97.88 Million USD | 6.36% |
| 2018 | 92.03 Million USD | -0.5% |
| 2017 | 92.49 Million USD | -6.03% |
| 2016 | 98.43 Million USD | -28.22% |
| 2015 | 137.13 Million USD | 39.43% |
| 2014 | 98.35 Million USD | 10.68% |
| 2013 | 88.86 Million USD | 36.74% |
| 2012 | 64.98 Million USD | 139.28% |
| 2011 | 27.15 Million USD | 143.97% |
| 2010 | 11.13 Million USD | 7.87% |
| 2009 | 10.31 Million USD | 16.61% |
| 2008 | 8.84 Million USD | 1.8% |
| 2007 | 8.69 Million USD | -4.54% |
| 2006 | 9.1 Million USD | 511.37% |
| 2005 | 1.48 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 12.42 Million USD | 2.99% |
| 2024 Q4 | 12.42 Million USD | 0.0% |
| 2024 FY | 49.82 Million USD | -35.12% |
| 2024 Q1 | 3.21 Million USD | -73.93% |
| 2024 Q2 | 12.06 Million USD | 274.85% |
| 2023 Q3 | 16.4 Million USD | -25.32% |
| 2023 Q1 | 17.5 Million USD | -20.53% |
| 2023 Q4 | 12.34 Million USD | -24.74% |
| 2023 FY | 76.79 Million USD | -15.42% |
| 2023 Q2 | 21.96 Million USD | 25.45% |
| 2022 Q3 | 21.35 Million USD | -13.21% |
| 2022 Q4 | 22.03 Million USD | 3.18% |
| 2022 FY | 90.78 Million USD | -21.1% |
| 2022 Q1 | 22.92 Million USD | 7.66% |
| 2022 Q2 | 24.6 Million USD | 7.33% |
| 2021 Q2 | 28.55 Million USD | -26.53% |
| 2021 Q1 | 38.86 Million USD | 18.89% |
| 2021 Q4 | 21.29 Million USD | -23.48% |
| 2021 FY | 115.05 Million USD | 6.97% |
| 2021 Q3 | 27.82 Million USD | -2.57% |
| 2020 Q4 | 32.69 Million USD | 17.93% |
| 2020 FY | 107.56 Million USD | 9.89% |
| 2020 Q3 | 27.72 Million USD | 6.94% |
| 2020 Q2 | 25.92 Million USD | 26.14% |
| 2020 Q1 | 20.55 Million USD | 5.19% |
| 2019 Q3 | 22.93 Million USD | -12.03% |
| 2019 Q2 | 26.06 Million USD | -8.28% |
| 2019 Q1 | 28.42 Million USD | 14.55% |
| 2019 FY | 97.88 Million USD | 6.36% |
| 2019 Q4 | 19.53 Million USD | -14.8% |
| 2018 Q1 | 20.66 Million USD | -13.6% |
| 2018 FY | 92.03 Million USD | -0.5% |
| 2018 Q3 | 24.67 Million USD | 10.42% |
| 2018 Q2 | 22.34 Million USD | 8.15% |
| 2018 Q4 | 24.81 Million USD | 0.54% |
| 2017 Q3 | 22.88 Million USD | -2.18% |
| 2017 Q4 | 23.91 Million USD | 4.51% |
| 2017 FY | 92.49 Million USD | -6.03% |
| 2017 Q2 | 23.39 Million USD | 5.03% |
| 2017 Q1 | 22.27 Million USD | -18.56% |
| 2016 Q2 | 24.84 Million USD | 14.38% |
| 2016 Q3 | 24.51 Million USD | -1.32% |
| 2016 FY | 98.43 Million USD | -28.22% |
| 2016 Q1 | 21.72 Million USD | -63.19% |
| 2016 Q4 | 27.35 Million USD | 11.56% |
| 2015 Q3 | 24.46 Million USD | -18.75% |
| 2015 Q4 | 59 Million USD | 141.18% |
| 2015 Q2 | 30.11 Million USD | 81.25% |
| 2015 Q1 | 16.61 Million USD | -13.46% |
| 2015 FY | 137.13 Million USD | 39.43% |
| 2014 Q2 | 16.06 Million USD | -10.69% |
| 2014 Q4 | 19.19 Million USD | -1.52% |
| 2014 FY | 98.35 Million USD | 10.68% |
| 2014 Q1 | 17.98 Million USD | 2.95% |
| 2014 Q3 | 19.49 Million USD | 21.32% |
| 2013 Q4 | 17.47 Million USD | -12.05% |
| 2013 FY | 88.86 Million USD | 36.74% |
| 2013 Q3 | 19.86 Million USD | 0.0% |
| 2012 FY | 64.98 Million USD | 139.28% |
| 2011 FY | 27.15 Million USD | 143.97% |
| 2010 FY | 11.13 Million USD | 7.87% |
| 2009 FY | 10.31 Million USD | 16.61% |
| 2008 FY | 8.84 Million USD | 1.8% |
| 2007 FY | 8.69 Million USD | -4.54% |
| 2006 FY | 9.1 Million USD | 511.37% |
| 2005 FY | 1.48 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -341.955% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -17.056% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 80.029% |
| Nascent Biotech, Inc. | 2.22 Million USD | -164.678% |
| Rebus Holdings, Inc. | 664 Thousand USD | -788.855% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 84.158% |
| Qrons Inc. | 643.67 Thousand USD | -816.92% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -1415.019% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 89.725% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -1320.529% |
| Skye Bioscience, Inc. | 13.54 Million USD | 56.435% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 93.199% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -20.01% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -2155.03% |
| SQZ Biotechnologies Company | 85.61 Million USD | 93.107% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -102.384% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -292.969% |
| Marizyme, Inc. | 19.23 Million USD | 69.324% |
| Genus plc | 147.7 Million USD | 96.004% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 32.773% |
| Pharming Group N.V. | 225.49 Million USD | 97.383% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -188.084% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -339.941% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 29.224% |
| ContraFect Corporation | 56.88 Million USD | 89.625% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -33.873% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -299.12% |
| IMV Inc. | 37.7 Million USD | 84.349% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -111.514% |
| MultiCell Technologies, Inc. | 567.42 USD | -1040046.629% |
| ONE Bio Corp. | 6.44 Million USD | 8.409% |
| Accustem Sciences Inc. | 3.74 Million USD | -57.537% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 93.133% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -1009.478% |
| Q BioMed Inc. | 3.43 Million USD | -71.738% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 76.12% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -124.622% |
| Biomind Labs Inc. | 994.18 Thousand USD | -493.654% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 94.058% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -235.402% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 12.147% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -216.568% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 23708.0% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 63.136% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -221.618% |
| GB Sciences, Inc. | 1.42 Million USD | -315.485% |
| Alpha Cognition Inc. | 9.7 Million USD | 39.19% |
| HST Global, Inc. | 140.9 Thousand USD | -4088.578% |
| CSL Limited | 3.44 Billion USD | 99.829% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -424.664% |
| Halberd Corporation | 74.84 Thousand USD | -7785.946% |
| Enzolytics Inc. | 2.17 Million USD | -170.795% |
| Agentix Corp. | 1.37 Million USD | -330.251% |
| Resverlogix Corp. | 12.71 Million USD | 53.571% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -61.667% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.615% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -465.326% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -145.412% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -273.697% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -73.334% |
| AVAX Technologies, Inc. | 7.31 Million USD | 19.264% |
| Zenith Capital Corp. | 8.94 Million USD | 34.004% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.285% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -33778.652% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -140.376% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -3341.219% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -207.251% |
| Kadimastem Ltd | 2.41 Million USD | -144.885% |
| Helix BioMedix, Inc. | 1.97 Million USD | -199.285% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 45.689% |
| BioStem Technologies, Inc. | 22.97 Million USD | 74.311% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -3152.059% |
| LadRx Corporation | 3.81 Million USD | -54.835% |
| Cell Source, Inc. | 4.32 Million USD | -36.452% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -539.083% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -539.083% |
| NovAccess Global Inc. | 2.46 Million USD | -139.261% |
| Affymax, Inc. | 39.38 Million USD | 85.015% |
| Itoco Inc. | 919.14 Thousand USD | -542.12% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -39.25% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -427.435% |
| Mobile Lads Corp. | 554.54 Thousand USD | -964.294% |
| CytoDyn Inc. | 18.05 Million USD | 67.316% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -23349.482% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -2581.776% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -315.695% |
| SYBLEU INC | 160.87 Thousand USD | -3568.664% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -224.943% |
| International Stem Cell Corporation | 5.27 Million USD | -11.971% |
| Bioxytran, Inc. | 3.82 Million USD | -54.497% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -11111.58% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -28912.437% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 83.726% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -264.771% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -702.082% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -89.714% |
| Neutra Corp. | 243.82 Thousand USD | -2320.628% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 66.191% |
| PureTech Health plc | 144.59 Million USD | 95.918% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 71.196% |
| IXICO plc | 4.7 Million USD | -25.388% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 32.909% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 94.988% |
| CSL Limited | 3.89 Billion USD | 99.848% |
| Cellectis S.A. | 97.32 Million USD | 93.935% |